The DOI matches its Crossref record.
IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells.
Abstract
rIL-6/B cell stimulatory factor 2 was found to augment CTL generation from mature as well as immature human T cells stimulated with UV-treated allogeneic cells. rIL-6 also acted on peanut agglutinin-positive murine thymocytes and Lyt-2-positive splenic T cells to give rise to CTL. rIL-6 alone could not induce CTL generation, the presence of IL-2 during the early phase of culture period was found to be essential for the IL-6 activity in the induction of CTL. The effect of rIL-6 was not mediated by the induction of IL-2 inasmuch as rIL-6 did not augment IL-2 production in MLC and anti-IL-2 antibody could not neutralize IL-6 activity. rIL-6 augmented CTL generation even when added 72 h after the initiation of cultures. The enhancing activity of rIL-6 could be neutralized with anti-IL-6 antibodies even when added 72 h after the initiation of cultures. The present data indicate that IL-6 acts in the late phase of CTL generation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
IL‐6 in inflammation, immunity, and disease
Tanaka, T., Narazaki, M., & Kishimoto, T. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016295 · Cited by 5,046
Self-citationInterleukin-6 and the acute phase response
Heinrich, P. C., Castell, J. V., & Andus, T. (1990) · Biochemical Journal · doi:10.1042/bj2650621 · Cited by 2,734
Kishimoto, T. (1989) · Blood · doi:10.1182/blood.v74.1.1.1 · Cited by 2,069
Self-citationVan Snick, J. (1990) · Annual Review of Immunology · doi:10.1146/annurev.iy.08.040190.001345 · Cited by 1,890
Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130
Taga, T., Hibi, M., Hirata, Y., Yamasaki, K., Yasukawa, K., Matsuda, T., Hirano, T., & Kishimoto, T. (1989) · Cell · doi:10.1016/0092-8674(89)90438-8 · Cited by 1,396
Self-citationInterleukin-6 in Biology and Medicine
Akira, S., Taga, T., & Kishimoto, T. (1993) · Advances in Immunology · doi:10.1016/s0065-2776(08)60532-5 · Cited by 1,389
Self-citationAge-Associated Increased Interleukin-6 Gene Expression, Late-Life Diseases, and Frailty
Ershler, W. B., & Keller, E. T. (2000) · Annual Review of Medicine · doi:10.1146/annurev.med.51.1.245 · Cited by 1,282
Application of acute phase protein measurements in veterinary clinical chemistry
Petersen, H. H., Nielsen, J. P., & Heegaard, P. M. H. (2004) · Veterinary Research · doi:10.1051/vetres:2004002 · Cited by 1,060
Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis
Hirano, T., Matsuda, T., Turner, M., Miyasaka, N., Buchan, G., Tang, B., Sato, K., Shimi, M., Maid, R., Feldmann, M., et al. (1988) · European Journal of Immunology · doi:10.1002/eji.1830181122 · Cited by 784
Self-citationImmunotherapeutic Implications of Il-6 Blockade for Cytokine Storm
Tanaka, T., Narazaki, M., & Kishimoto, T. (2016) · Immunotherapy · doi:10.2217/imt-2016-0020 · Cited by 708
Self-citationInflammatory Cytokines Provide a Third Signal for Activation of Naive CD4+ and CD8+ T Cells
Curtsinger, J. M., Schmidt, C. S., Mondino, A., Lins, D. C., Kedl, R. M., Jenkins, M. K., & Mescher, M. F. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.6.3256 · Cited by 616
Interleukin 6 is required for the development of collagen-induced arthritis
Alonzi, T., Fattori, E., Lazzaro, D., Costa, P., Probert, L., Kollias, G., De Benedetti, F., Poli, V., & Ciliberto, G. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.4.461 · Cited by 604
“Since IL-6 functions as a late-acting killer helper factor in the differentiation of CTLs (42), and CD81 T cells play an important role in CIA initiation (39, 43), IL-6 ablation may, for example, provoke a decrease in MHC class I–restricted anti-CII cytotoxic activity.”
BackgroundThe soluble interleukin‐6 receptor is generated by shedding
Mülberg, J., Schooltink, H., Stoyan, T., Günther, M., Graeve, L., Buse, G., Mackiewicz, A., Heinrich, P. C., & Rose‐John, S. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230226 · Cited by 506
Le, J., & Vilček, J. (1990) · Pathology Reviews • 1990 · doi:10.1007/978-1-4612-0485-5_7 · Cited by 474
Tumor necrosis factor-?, interleukin-1?, and interleukin-6 expression in inflammatory bowel disease
Stevens, C., Walz, G., Singaram, C., Lipman, M. L., Zanker, B., Muggia, A., Antonioli, D., Peppercorn, M. A., & Strom, T. B. (1992) · Digestive Diseases and Sciences · doi:10.1007/bf01300378 · Cited by 331
Regulation of human cytolytic lymphocyte responses by interleukin-12
Gately, M. K., Wolitzky, A. G., Quinn, P. M., & Chizzonite, R. (1992) · Cellular Immunology · doi:10.1016/0008-8749(92)90011-d · Cited by 321
The soluble Interleukin 6 receptor: Generation and role in inflammation and cancer
Chalaris, A., Garbers, C., Rabe, B., Rose-John, S., & Scheller, J. (2011) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2010.10.007 · Cited by 289
Isshiki, H., Akira, S., Tanabe, O., Nakajima, T., Shimamoto, T., Hirano, T., & Kishimoto, T. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.6.2757 · Cited by 285
Self-citationInterleukin 6: at the interface of human health and disease
Grebenciucova, E., & VanHaerents, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1255533 · Cited by 281
Pathogenesis of Takayasu's arteritis: A 2011 update
Arnaud, L., Haroche, J., Mathian, A., Gorochov, G., & Amoura, Z. (2011) · Autoimmunity Reviews · doi:10.1016/j.autrev.2011.08.001 · Cited by 278
Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study
Lee, W.-J., Lee, S.-T., Moon, J., Sunwoo, J.-S., Byun, J.-I., Lim, J.-A., Kim, T.-J., Shin, Y.-W., Lee, K.-J., Jun, J.-S., et al. (2016) · Neurotherapeutics · doi:10.1007/s13311-016-0442-6 · Cited by 271
Therapeutic Targeting of the Interleukin-6 Receptor
Tanaka, T., Narazaki, M., & Kishimoto, T. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134715 · Cited by 262
Self-citationCD11b+ Peyer’s Patch Dendritic Cells Secrete IL-6 and Induce IgA Secretion from Naive B Cells
Sato, A., Hashiguchi, M., Toda, E., Iwasaki, A., Hachimura, S., & Kaminogawa, S. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.7.3684 · Cited by 257
Dysregulated interleukin 6 expression produces a syndrome resembling Castleman’s disease in mice
Brandt, S. J., Bodine, D. M., Dunbar, C. E., & Nienhuis, A. W. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114749 · Cited by 248
Pillinger, T., Osimo, E. F., Brugger, S., Mondelli, V., McCutcheon, R. A., & Howes, O. D. (2019) · Schizophrenia Bulletin · doi:10.1093/schbul/sby160 · Cited by 190
IL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19
Kishimoto, T., & Kang, S. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101220-023458 · Cited by 140
Self-citationRecombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients
Nieken, J., Mulder, N., Buter, J., Vellenga, E., Limburg, P., Piers, D., & de Vries, E. (1995) · Blood · doi:10.1182/blood.v86.3.900.900 · Cited by 128
Hirano, T., & Kishimoto, T. (1990) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-49295-2_14 · Cited by 57
Self-citation
Metadata
- Authors
- Okada, M., Kitahara, M., Kishimoto, S., Matsuda, T., Hirano, T., & Kishimoto, T.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1988-09-01
- Volume
- 141
- Issue
- 5
- Pages
- 1543-1549
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1543188088
- Cited by
- 359
- References
- 0
- FWCI
- 10.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.